Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Fresenius Medical Care ( (FMS) ) just unveiled an announcement.
Fresenius Medical Care announced the termination of legal proceedings regarding objections to a resolution passed at their Extraordinary General Meeting in July 2023. The case, which involved a change in the company’s legal form to a stock corporation, was resolved as all shareholders withdrew their objections without any agreements being reached with the company. This termination potentially stabilizes the company’s legal standing and supports its strategic transformation efforts.
More about Fresenius Medical Care
Fresenius Medical Care is a prominent entity in the healthcare sector, primarily focusing on the development and provision of dialysis products and services. It serves a global market with a strong emphasis on improving the quality of life for patients with chronic kidney failure.
YTD Price Performance: 16.90%
Average Trading Volume: 271,653
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $13.95B
For a thorough assessment of FMS stock, go to TipRanks’ Stock Analysis page.